Janssen Belgium

XO1 Ltd is a biotechnology company focused on developing ichorcumab, an innovative anti-thrombin antibody designed to prevent heart attacks and strokes without the risk of bleeding. Operating as a virtual company, XO1 does not maintain physical office or laboratory space; instead, it collaborates with skilled contract research and development specialists across Europe and the United States. This model allows for efficient cost management and the flexibility to select the most suitable suppliers for specific tasks. The company aims to create a breakthrough anticoagulant drug that mimics the activity of a natural human antibody, offering a promising solution to the challenges associated with existing anticoagulant therapies.

Quanticare Technologies specializes in healthcare technology aimed at enhancing the safety and well-being of seniors. The company has developed an innovative sensor system for walking frames that helps prevent falls, a significant concern for older adults. Additionally, Quanticare's platform allows users to monitor and track their health conditions proactively. By enabling patients to collect and analyze their health data, the technology facilitates early intervention by healthcare practitioners, allowing for timely responses to potential health issues. This dual focus on fall prevention and proactive health monitoring positions Quanticare as a key player in improving the quality of life for seniors.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany. The company specializes in creating innovative therapeutics and diagnostics aimed at treating heart and vascular diseases, particularly those that currently have unmet medical needs. Corimmun's expertise encompasses the entire spectrum of drug development, from initial research through to commercialization, positioning it as a key player in the field of cardiovascular therapeutics.

Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing innovative small-molecule drugs for serious diseases. The company has established itself as a leader in the treatment of cystic fibrosis with its key therapies, including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which are recognized as the standard of care worldwide. In addition to its cystic fibrosis portfolio, Vertex is expanding its capabilities with Casgevy, a gene-editing therapy aimed at treating beta thalassemia and sickle-cell disease. The company is also exploring small-molecule inhibitors for managing acute and chronic pain without opioids, as well as targeting APOL1-mediated kidney diseases. Vertex's ongoing research includes developing cell therapies that aim to restore functional capabilities in affected patients, reflecting its commitment to addressing a broad range of serious health challenges.